The Drug-Induced Respiratory Disease Website
Continuing treatment with osimertinib can be a reasonable option (PMID 31882494).
Publications
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Chest 2022 Nov;162;1188-1198 — 2022 Nov — 1188-1198
Pneumonia caused by crizotinib: case report and review of literature.
Annals of palliative medicine 2021 Apr;10;4932-4937 — 2021 Apr — 4932-4937
Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Investigational new drugs 2021 04;39;571-577 — 2021 04 — 571-577
Uchida T, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, Hashimoto K, Nishihara F, Murayama Y, Kobayashi K, Kagamu H
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.
Thoracic cancer 2019 04;10;975-979 — 2019 04 — 975-979
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramali
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
The New England journal of medicine 2018 01 11;378;113-125 — 2018 01 11 — 113-125
Matsumoto Y, Kawaguchi T, Yamamoto N, Sawa K, Yoshimoto N, Suzumura T, Watanabe T, Mitsuoka S, Asai K, Kimura T, Yoshimura N, Kuwae Y, Hirata K
Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer.
Internal medicine (Tokyo, Japan) 2017 Sep 01;56;2325-2328 — 2017 Sep 01 — 2325-2328
Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Apr 20;35;1288-1296 — 2017 Apr 20 — 1288-1296
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA,
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
The New England journal of medicine 2017 02 16;376;629-640 — 2017 02 16 — 629-640
Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 12;11;2051-2052 — 2016 12 — 2051-2052
Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 12;11;2253-2258 — 2016 12 — 2253-2258
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody.
Investigational new drugs 2017 02;35;105-107 — 2017 02 — 105-107
AZD9291-induced Acute Interstitial Lung Disease.
Chinese medical journal 2016 Jun 20;129;1507-8 — 2016 Jun 20 — 1507-8